Bovine herpes mammillitis virus or bovine herpesvirus type 2 (BHV-2) c
auses ulcerative lesions on the teats and udders of infected cows. Sin
ce no commercial vaccine is available for this disease, we investigate
d certain experimental BHV-2 vaccines against this virus in infected g
uinea pigs. Vaginally infected guinea pigs get severe, self-limiting v
aginal infections characterized by erythema and swelling and the produ
ction of measurable vaginal virus titers. Two vaccine approaches were
investigated: vaccination with wild-type (WT) virus by the subcutaneou
s route, and vaccination either subcutaneously or intravaginally with
a thymidine kinase (TK) deficient (TK-) virus. The TK- strain was prep
ared by passage of BHV-2 in the presence of the potent TK-dependent an
tiviral agent -2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU
). The antiviral activity of FMAU against the virus in plaque reductio
n assays changed from 0.05 to 2 mu M at the same time that the TK acti
vity of the mutant virus decrease to 7% of WT virus TK activity. Subcu
taneous vaccination of guinea pigs with WT and TK- viruses did not ind
uce vaginal infection. Primary vaginal infection (vaccination) with th
e TK- virus led to greatly reduced lesion severity compared to vaginal
infection with the WT virus. However, the amount of vaginal virus tit
ers recovered during these primary infections was similar for both TK-
and WT viruses, indicating that both viruses had equal infecting pote
ntial. Thirty days after vaccination the animals were re-infected intr
avaginally with WT virus. The vaccinated animals showed dramatically r
educed lesion severity and low recoverable virus titers compared to ag
e-matched nonvaccinated animals. These results indicate the potential
of a TK- vaccine given by two different routes or a WT virus administe
red by a nonvaginal route to protect BHV-2-infected guinea pigs. These
approaches may have application to the vaccination of dairy cattle su
sceptible to BHV-2 infection.